Search Results
Feb 04, 2026, 18:15 ET Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, February 10. Sanofi is acquiring Dynavax Technologies in a deal expected
More news about: S&P Dow Jones Indices
Jan 06, 2026, 10:50 ET Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-dbrg-fold-dvax-shareholders-to-contact-the-firm-to-discuss-their-rights-302653874.htmlSOURCE
More news about: Halper Sadeh LLP
Jan 05, 2026, 14:22 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
DVAX) related to its sale to Sanofi. Under the terms of the proposed transaction, Dynavax shareholders are expected to receive $15.50 per share in cash. Is
More news about: Monteverde & Associates PC
Dec 30, 2025, 19:16 ET Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Dynavax will receive $15.50 in cash for each share of Dynavax that
More news about: Kahn Swick & Foti, LLC
Dec 30, 2025, 10:20 ET Halper Sadeh LLC Encourages DVAX, CWAN, DBRG Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-dvax-cwan-dbrg-shareholders-to-contact-the-firm-to-discuss-their-rights-302650666.htmlSOURCE
More news about: Halper Sadeh LLP
Dec 29, 2025, 12:00 ET Shareholder Alert: The Ademi Firm investigates whether DigitalBridge Group, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Dec. 29, 2025 /PRNewswire/ -- The Ademi Firm is investigating DigitalBridge (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with SoftBank.
More news about: Ademi LLP
Dec 24, 2025, 11:30 ET Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Dec. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Dynavax (Nasdaq: DVAX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Sanofi.
More news about: Ademi LLP
Dec 24, 2025, 01:23 ET Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition
More news about: Dynavax Technologies
Nov 19, 2025, 16:01 ET Dynavax to Participate at the 8th Annual Evercore Healthcare Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate
More news about: Dynavax Technologies
Nov 05, 2025, 16:01 ET Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business
More news about: Dynavax Technologies
Nov 05, 2025, 16:00 ET Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology
More news about: Dynavax Technologies
Oct 22, 2025, 16:01 ET Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on
More news about: Dynavax Technologies
Oct 21, 2025, 16:01 ET Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
EMERYVILLE, Calif., Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1
More news about: Dynavax Technologies